Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128399 | 0.85 | CYP3A4 (0.59) | CYP3A4ALDH1A1DRD1FLT3CYP2C9 | |
| SCHEMBL2200991 | 0.78 | PI4KA (0.59) | ALDH1A1FLT3CYP2C9TP53NFKB1 | |
| SCHEMBL2198668 | 0.78 | MERTK (0.53) | ABL1BCRDRD1FLT3 | |
| SCHEMBL2198672 | 0.77 | CYP3A4 (0.37) | CYP3A4ABL1DRD1FLT3HPGD | |
| SCHEMBL1128620 | 0.75 | CYP2C19 (0.41) | ALDH1A1LMNAPOLBCYP2C9TP53 | |
| SCHEMBL12362928 | 0.75 | ALDH1A1 (0.45) | CYP3A4ALDH1A1LMNAPOLBDRD1 | |
| SCHEMBL1790658 | 0.75 | MERTK (0.47) | ALDH1A1LMNAPOLBFLT3MAPK1 | |
| SCHEMBL19464040 | 0.74 | ALDH1A1 (0.46) | ALDH1A1LMNAPOLB | |
| SCHEMBL16809888 | 0.72 | CYP2C19 (0.39) | ALDH1A1LMNAPOLBCYP2C9TP53 | |
| SCHEMBL2020756 | 0.72 | CYP3A4 (0.79) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977345-B2 | c-MET modulators and method of use | EXELIXIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-1773826-A4 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1773826-A2 | C-MET MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014325-A2 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | CYP3A4 2050/4885ALDH1A1 2382/4885LMNA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.